Yahoo Finance 
Vaginitis Therapeutics Global Market Landscape Analysis 2023-2030: New Treatment Avenues and Key Company Innovations Propel the Industry
Dublin, Jan. 11, 2024 (GLOBE NEWSWIRE) -- The "Vaginitis Therapeutics Market Size, Share & Trends Analysis, 2023-2030" report has been added to ResearchAndMarkets.com's offering.
The global vaginitis therapeutics market is expected to reach USD 6 billion by 2030, registering a CAGR of 8.3% from 2023 to 2030. Supportive initiatives by government and non-government agencies to increase awareness level among women is driving the demand for vaginitis drugs. Increased consumption of alcohol is also estimated to fuel the adoption of these drugs. Around 5.3 million women in the U.S. are at risk related to health and general well-being.
Furthermore, rising R&D activities for vaginitis therapeutics is anticipated to accelerate the market growth. National Institute of Allergy and Infectious Diseases (NIAID)-funded research has discovered various important data about yeast generative behavior, which could result in new way of treatment for yeast infections. In addition, introduction of new drugs by key companies is expected to propel the market growth. For instance, in September 2017, Symbiomix Therapeutics received FDA approval for Solosec (secnidazole) for the treatment of bacterial vaginosis.
Vaginitis Therapeutics Market Report Highlights
Anti-bacterial segment led the market for vaginitis therapeutics with a revenue share of 37.9% in 2022 owing to the availability of a wide product range and higher number of cases of bacterial vaginosis disease
Hormone is expected to witness lucrative growth with a CAGR of 8.4% over the forecast period due to the presence of pipeline products and rising adoption of products
The prescription segment led the market with the largest revenue share of 51.2% in 2022, owing to the higher efficacy and safety of prescribed drugs and availability of a wide range of drugs for severe and recurring vaginitis
Over the counter segment is expected to expand at a CAGR of 8.7% in the coming years due to increasing number of FDA approvals for the treatment of mild vaginitis
North America dominated the market with a revenue share of 38.3% in 2022, in terms of revenue, owing to of high-quality healthcare services and increasing cases of vaginitis
Asia Pacific is estimated to witness the fastest growth, with a CAGR of around 9.5% over the forecast period. This growth is attributed to favorable government initiatives and rising disposable income along with the presence of a large target population base.
Key Attributes
Report Attribute | Details |
No. of Pages | 75 |
Forecast Period | 2022-2030 |
Estimated Market Value (USD) in 2022 | $3.2 Billion |
Forecasted Market Value (USD) by 2030 | $6 Billion |
Compound Annual Growth Rate | 8.3% |
Regions Covered | Global |
Key Topics Covered
Chapter 1. Methodology and Scope
Chapter 2. Executive Summary
Chapter 3. Vaginitis Therapeutics Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Penetration & Growth Prospect Mapping
3.3. Market Dynamics
3.3.1. Market driver analysis
3.3.2. Market restraint analysis
3.4. Vaginitis Therapeutics Market Analysis Tools
3.4.1. Industry Analysis - Porter's Five Forces
3.4.1.1. Supplier power
3.4.1.2. Buyer power
3.4.1.3. Substitution threat
3.4.1.4. Threat of new entrant
3.4.1.5. Competitive rivalry
3.4.2. PESTEL Analysis
3.4.2.1. Political landscape
3.4.2.2. Technological landscape
3.4.2.3. Economic landscape
Chapter 4. Vaginitis Therapeutics Market: Disease Type Estimates & Trend Analysis
4.1. Vaginitis Therapeutics Market: Disease Type Key Takeaways
4.2. Vaginitis Therapeutics Market: Disease Type Movement & Market Share Analysis, 2022 & 2030
4.3. Anti-fungal
4.4. Anti-bacterial
4.5. Hormone
Chapter 5. Vaginitis Therapeutics Market: Product Estimates & Trend Analysis
5.1. Vaginitis Therapeutics Market: Product Key Takeaways
5.2. Vaginitis Therapeutics Market: Product Movement & Market Share Analysis, 2022 & 2030
5.3. Over-the-counter
5.4. Prescription
Chapter 6. Vaginitis Therapeutics Market: Regional Estimates & Trend Analysis
6.1. Regional Outlook
6.2. Vaginitis Therapeutics Market by Region: Key Takeaways
6.3. North America
6.4. Europe
6.5. Asia Pacific
6.6. Latin America
6.7. MEA
Chapter 7. Competitive Landscape
7.1. Recent Developments & Impact Analysis, By Key Market Participants
7.2. Market Participant Categorization
7.2.1. Symbiomix Therapeutics LLC
7.2.2. Merck & Co. Inc.
7.2.3. Pfizer Inc.
7.2.4. Novartis AG
7.2.5. Teva Pharmaceutical Industries Ltd.
7.2.6. Bayer AG
7.2.7. Janssen Pharmaceuticals Inc.
7.2.8. Lupin Pharmaceuticals Inc.
7.2.9. Lumavita AG
7.2.10. Mission Pharmacal Company
For more information about this report visit https://www.researchandmarkets.com/r/b8hlzq
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood,Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
